From: Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)
Baseline | Follow-up | ||||||
---|---|---|---|---|---|---|---|
Visit | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
Week | 0 | 2 | 4 | 6 | 8 | 48 | 52 |
Month | Apr 2020 | May 2020 | May 2020 | Jun 2020 | Jun 2020 | Mar 2021 | Apr – Jun 2021 |
Questionnaire | |||||||
Inclusion / Exclusion criteria | • | ||||||
SARS-CoV-2 exposure and infection | • | • | • | • | • | • | • |
Epidemiological factors | • | • | • | • | • | • | • |
Demographics | • | • | • | ||||
Education / Professional background | • | • | • | • | • | • | • |
Home and social contacts | • | • | • | • | • | • | • |
Socio-economic status a | • | • | • | • | • | • | • |
Comorbidities | • | • | • | • | • | • | |
Current medications | • | • | • | ||||
Respiratory symptoms onset | • | • | • | • | • | • | |
Signs and symptoms | • | • | • | • | • | • | • |
Symptoms onset and initial clinical signs of SARS-CoV-2 infection | • | ||||||
SARS-CoV-2 vaccine | • | • | |||||
Environmental conditions at home with a diagnosis of COVID-19 | • | • | • | • | • | • | |
Contact tracing information | • | • | • | • | • | • | |
Behavioural analysis during COVID-19 pandemic b | • | • | • | • | • | • | • |
Psychological questionnaires | |||||||
CES-Da | • | • | • | • | • | • | • |
GAD-7a | • | • | • | • | • | • | • |
UCLA short versiona | • | • | • | • | • | • | • |
PSS-4a | • | • | • | • | • | • | • |
BRSa | • | • | • | • | • | • | • |
BFI-10 | • | • | • | • | • | • | |
Major life events | |||||||
Childhood Trauma Questionnaire | • | ||||||
Samples | • | • | • | • | • | • | |
Serum | • | • | • | • | • | • | |
Plasma | • | • | • | • | • | • | |
Buffy Coat | • | • | • | • | • | • | |
PBMCs | • | ||||||
Combined naso/oropharyngeal swab | • | • | • | • | • | • | |
Stool samplea | • | • | • | • | • | • | |
SARS-CoV-2 diagnostics | • | • | • | • | • | • | |
IgA, IgG-S anti-SARS-CoV-2 antibodies measurements | • | • | • | • | • | • | |
IgG-N anti-SARS-CoV-2 antibodies measurements | • | ||||||
SARS-CoV-2 neutralisation capacity of antibodies | • | ||||||
RT-qPCR against SARS-CoV-2 | • | • | • | • | • | • |